The basic shape of a retatrutide schedule
Retatrutide dosing follows a step pattern, not a single fixed amount. Every published schedule starts at a low dose, holds it for a few weeks, then moves up by a fixed increment. The point isn’t to reach the highest dose fast. It’s to give the gut time to adjust before the next step, since a jump straight to a target dose is what causes the worst nausea.
The trial schedule used in Eli Lilly’s phase 2 and phase 3 work moved in 2mg to 4mg increments roughly every four weeks, starting at 2mg and topping out anywhere from 4mg to 12mg depending on the arm. That’s a reference point, not a rule everyone follows exactly, since real-world titration often moves more slowly if side effects are strong.
Why four-week steps, specifically
Retatrutide has a long half-life, so it takes several doses before blood levels settle into a steady state. Moving the dose again before that happens makes it harder to tell whether a side effect comes from the new step or hasn’t caught up from the last one. Four weeks is roughly the point where levels have mostly levelled off.
What a step actually changes
Each increase raises how strongly the drug affects appetite and gut motility, which is why nausea tends to reappear, in a smaller form, right after a step. Most people report it settling within a few days, similar to the first week at the starting dose.
Reading a schedule table
A typical schedule sheet lists the week number, the dose for that week, and how long to hold before the next step. Some UK suppliers include one with the paperwork on a COA-verified listing; others expect the buyer to source one separately. Either way, the numbers should match a range that’s actually been reported in trial data, not a schedule invented by a seller with no source.
What this page isn’t
This is a description of how published schedules are structured, not personal dosing instruction. What’s right for one person’s step-up pace depends on their own response and isn’t something a blog post can safely tell you.